225 related articles for article (PubMed ID: 30867138)
1. Anti-metastatic activity of MPT0G211, a novel HDAC6 inhibitor, in human breast cancer cells in vitro and in vivo.
Hsieh YL; Tu HJ; Pan SL; Liou JP; Yang CR
Biochim Biophys Acta Mol Cell Res; 2019 Jun; 1866(6):992-1003. PubMed ID: 30867138
[TBL] [Abstract][Full Text] [Related]
2. Targeting HSP90-HDAC6 Regulating Network Implicates Precision Treatment of Breast Cancer.
Yu S; Cai X; Wu C; Liu Y; Zhang J; Gong X; Wang X; Wu X; Zhu T; Mo L; Gu J; Yu Z; Chen J; Thiery JP; Chai R; Chen L
Int J Biol Sci; 2017; 13(4):505-517. PubMed ID: 28529458
[TBL] [Abstract][Full Text] [Related]
3. The anticancer effects of MPT0G211, a novel HDAC6 inhibitor, combined with chemotherapeutic agents in human acute leukemia cells.
Tu HJ; Lin YJ; Chao MW; Sung TY; Wu YW; Chen YY; Lin MH; Liou JP; Pan SL; Yang CR
Clin Epigenetics; 2018 Dec; 10(1):162. PubMed ID: 30594243
[TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylase Inhibitor Enhances the Efficacy of MEK Inhibitor through NOXA-Mediated MCL1 Degradation in Triple-Negative and Inflammatory Breast Cancer.
Torres-Adorno AM; Lee J; Kogawa T; Ordentlich P; Tripathy D; Lim B; Ueno NT
Clin Cancer Res; 2017 Aug; 23(16):4780-4792. PubMed ID: 28465444
[No Abstract] [Full Text] [Related]
5. Hsp90 Inhibition Results in Glucocorticoid Receptor Degradation in Association with Increased Sensitivity to Paclitaxel in Triple-Negative Breast Cancer.
Agyeman AS; Jun WJ; Proia DA; Kim CR; Skor MN; Kocherginsky M; Conzen SD
Horm Cancer; 2016 Apr; 7(2):114-26. PubMed ID: 26858237
[TBL] [Abstract][Full Text] [Related]
6. Propolin G-Suppressed Epithelial-to-Mesenchymal Transition in Triple-Negative Breast Cancer Cells via Glycogen Synthase Kinase 3β-Mediated Snail and HDAC6-Regulated Vimentin Degradation.
Pai JT; Chen XH; Leu YL; Weng MS
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163593
[TBL] [Abstract][Full Text] [Related]
7. Zhuidu Formula suppresses the migratory and invasive properties of triple-negative breast cancer cells via dual signaling pathways of RhoA/ROCK and CDC42/MRCK.
Wu Q; Ma X; Jin Z; Ni R; Pan Y; Yang G
J Ethnopharmacol; 2023 Oct; 315():116644. PubMed ID: 37196814
[TBL] [Abstract][Full Text] [Related]
8. Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells.
Ha K; Fiskus W; Choi DS; Bhaskara S; Cerchietti L; Devaraj SG; Shah B; Sharma S; Chang JC; Melnick AM; Hiebert S; Bhalla KN
Oncotarget; 2014 Jul; 5(14):5637-50. PubMed ID: 25026298
[TBL] [Abstract][Full Text] [Related]
9. Low Dose of Paclitaxel Combined with XAV939 Attenuates Metastasis, Angiogenesis and Growth in Breast Cancer by Suppressing Wnt Signaling.
Shetti D; Zhang B; Fan C; Mo C; Lee BH; Wei K
Cells; 2019 Aug; 8(8):. PubMed ID: 31416135
[TBL] [Abstract][Full Text] [Related]
10. Tektin4 loss promotes triple-negative breast cancer metastasis through HDAC6-mediated tubulin deacetylation and increases sensitivity to HDAC6 inhibitor.
Ge LP; Jin X; Yang YS; Liu XY; Shao ZM; Di GH; Jiang YZ
Oncogene; 2021 Mar; 40(12):2323-2334. PubMed ID: 33654196
[TBL] [Abstract][Full Text] [Related]
11. Combination of the novel histone deacetylase inhibitor YCW1 and radiation induces autophagic cell death through the downregulation of BNIP3 in triple-negative breast cancer cells in vitro and in an orthotopic mouse model.
Chiu HW; Yeh YL; Wang YC; Huang WJ; Ho SY; Lin P; Wang YJ
Mol Cancer; 2016 Jun; 15(1):46. PubMed ID: 27286975
[TBL] [Abstract][Full Text] [Related]
12. AMG 900, a small-molecule inhibitor of aurora kinases, potentiates the activity of microtubule-targeting agents in human metastatic breast cancer models.
Bush TL; Payton M; Heller S; Chung G; Hanestad K; Rottman JB; Loberg R; Friberg G; Kendall RL; Saffran D; Radinsky R
Mol Cancer Ther; 2013 Nov; 12(11):2356-66. PubMed ID: 23990115
[TBL] [Abstract][Full Text] [Related]
13. Riluzole synergizes with paclitaxel to inhibit cell growth and induce apoptosis in triple-negative breast cancer.
Speyer CL; Bukhsh MA; Jafry WS; Sexton RE; Bandyopadhyay S; Gorski DH
Breast Cancer Res Treat; 2017 Nov; 166(2):407-419. PubMed ID: 28780701
[TBL] [Abstract][Full Text] [Related]
14. Suppression of triple-negative breast cancer metastasis by pan-DAC inhibitor panobinostat via inhibition of ZEB family of EMT master regulators.
Rhodes LV; Tate CR; Segar HC; Burks HE; Phamduy TB; Hoang V; Elliott S; Gilliam D; Pounder FN; Anbalagan M; Chrisey DB; Rowan BG; Burow ME; Collins-Burow BM
Breast Cancer Res Treat; 2014 Jun; 145(3):593-604. PubMed ID: 24810497
[TBL] [Abstract][Full Text] [Related]
15. Combination of pan-histone deacetylase inhibitor and autophagy inhibitor exerts superior efficacy against triple-negative human breast cancer cells.
Rao R; Balusu R; Fiskus W; Mudunuru U; Venkannagari S; Chauhan L; Smith JE; Hembruff SL; Ha K; Atadja P; Bhalla KN
Mol Cancer Ther; 2012 Apr; 11(4):973-83. PubMed ID: 22367781
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel PAK1/HDAC6 dual inhibitor ZMF-23 that triggers tubulin-stathmin regulated cell death in triple negative breast cancer.
Zhang J; Chen X; Chen G; Wang H; Jia L; Hao Y; Yao D
Int J Biol Macromol; 2023 Nov; 251():126348. PubMed ID: 37586623
[TBL] [Abstract][Full Text] [Related]
17. Bazedoxifene is a novel IL-6/GP130 inhibitor for treating triple-negative breast cancer.
Tian J; Chen X; Fu S; Zhang R; Pan L; Cao Y; Wu X; Xiao H; Lin HJ; Lo HW; Zhang Y; Lin J
Breast Cancer Res Treat; 2019 Jun; 175(3):553-566. PubMed ID: 30852762
[TBL] [Abstract][Full Text] [Related]
18. The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.
Marcus AI; Zhou J; O'Brate A; Hamel E; Wong J; Nivens M; El-Naggar A; Yao TP; Khuri FR; Giannakakou P
Cancer Res; 2005 May; 65(9):3883-93. PubMed ID: 15867388
[TBL] [Abstract][Full Text] [Related]
19. NEDD9 regulates actin dynamics through cortactin deacetylation in an AURKA/HDAC6-dependent manner.
Kozyreva VK; McLaughlin SL; Livengood RH; Calkins RA; Kelley LC; Rajulapati A; Ice RJ; Smolkin MB; Weed SA; Pugacheva EN
Mol Cancer Res; 2014 May; 12(5):681-93. PubMed ID: 24574519
[TBL] [Abstract][Full Text] [Related]
20. Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.
Proia DA; Zhang C; Sequeira M; Jimenez JP; He S; Spector N; Shapiro GI; Tolaney S; Nagai M; Acquaviva J; Smith DL; Sang J; Bates RC; El-Hariry I
Clin Cancer Res; 2014 Jan; 20(2):413-24. PubMed ID: 24173541
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
